Abstract
Thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are used to treat acute lymphoblastic leukemia of childhood. To test the hypothesis that variation in the expression of genes within the “thiopurine pathway” might influence 6-MP and 6-TG sensitivity, we generated basal gene expression profiles and IC50 values for both of these thiopurine drugs using a model system consisting of 194 Human Variation Panel lymphoblastoid cell lines. Association analysis showed that thiopurine S-methyltransferase, ecto-5′-nucleotidase (NT5E), and multidrug resistance protein 4 (ABCC4) expression were correlated with thiopurine cytotoxicity. Those observations suggested the possible existence of a “thiopurine cellular circulation” involving nucleotide efflux by ABCC4, hydrolysis of thiopurine nucleotide monophosphates outside of the cell by NT5E, and subsequent transport of thiopurine nucleosides back into the cell by nucleoside transporters. The existence of this cellular circulation was confirmed by a series of functional experiments performed with cultured cells stably or transiently transfected with ABCC4 and/or NT5E. Because of the central role of NT5E in this cellular circulation, the NT5E gene was resequenced using 287 DNA samples from three ethnic groups, with the identification of 68 single nucleotide polymorphisms (SNPs), 46 of which were novel. Several SNPs in the 5′-flanking region of NT5E were highly correlated with expression, rs9450278 having the lowest p value (p = 2.4 × 10−10, R = −0.376). The thiopurine cellular circulation and genetic polymorphisms for genes encoding the proteins involved should be incorporated into future studies of thiopurine drug therapy and effect.
Footnotes
This study was supported in part by the National Institutes of Health National Institute of General Medical Sciences [Grants R01-GM28157, U01-GM61388 (The Pharmacogenomics Research Network)]; the National Institutes of Health National Cancer Institute [Grants R01-CA132780, R01-CA138461, K22-CA130828]; an American Society for Pharmacology and Experimental Therapeutics Astellas Award; and a PhRMA Foundation “Center of Excellence in Clinical Pharmacology” Award.
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.110.035220.
↵
The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- 6-MP
- 6-mercaptopurine
- 6-TG
- 6-thioguanine
- ALL
- acute lymphoblastic leukemia
- 6-TGN
- 6-thioguanine nucleotide
- RBC
- red blood cell
- TPMT
- thiopurine S-methyltransferase
- ABCC4/MRP4
- multidrug resistance protein 4
- NT5E
- ecto-5′-nucleotidase
- SNP
- single nucleotide polymorphism
- FR
- flanking region
- TGrib
- 6-thioguanine ribonucleoside
- TGMP
- 6-thioguanine monophosphate
- EA
- European-American
- AA
- African-American
- HCA
- Han Chinese-American
- PCR
- polymerase chain reaction
- kb
- kilobase
- RT
- reverse transcriptase
- q
- quantitative
- HPLC
- high-performance liquid chromatography
- HEK
- human embryonic kidney
- SLC
- solute carrier
- MAF
- minor allele frequency
- LD
- linkage disequilibrium
- TIMP
- thioinosine monophosphate.
- Received June 30, 2010.
- Accepted September 20, 2010.
- Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|